More than sixty 340B advocates braved an excessive heat warning in the nation’s capital yesterday afternoon for the third annual [...] …
Year: 2024
SPONSORED CONTENT
While federal laws and regulations set the foundation for 340B compliance, state-level laws introduce an additional layer of complexity. Covered entities (CEs) must be vigilant in understanding how these state laws can impact their operations to avoid potential compliance pitfalls. We have outlined a few
…
As hospital advocates prepared to begin their annual summer visits to Capitol Hill this week, five congressional Democrats signed on [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An anti-government waste group with ties to the drug industry is urging lawmakers to “stop the feeding frenzy” in the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: In Tuesday’s issue, we looked at comments from 340B provider stakeholders, today we look more closely at the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
New Hampshire Gov. Chris Sununu (R) yesterday signed a law prohibiting payers and pharmacy benefit managers (PBMs) from “discriminating against [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Canadian drug manufacturer recently announced that it will refund covered entities for hundreds of different products purchased between 2021 [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: In today’s issue, we look at the 340B provider community’s comments to CMS. In a future issue, we [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Japanese drug manufacturer has ended its 340B contract pharmacy restrictions in Maryland and Mississippi in conjunction with new contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
As the 340B program continues to grow in complexity, given the drug manufacturer restrictions, it is more important than ever for covered entities to have a firm grasp and understanding of the fees charged by their Third Party Adminisrators (TPAs) for their contract pharmacies. Whether it is
…